nmda receptor antagonist memantine  (Boehringer Ingelheim)

Journal: Psychopharmacology

Article Title: Memantine treatment does not affect compulsive behavior or frontostriatal connectivity in an adolescent rat model for quinpirole-induced compulsive checking behavior

doi: 10.1007/s00213-022-06139-z

Figure Lengend Snippet: Functional and structural connectivity in the frontostriatal system before and after saline/memantine treatment in control and compulsive rats. Bar graphs of functional connectivity (Fisher’s Z-transformed correlation coefficient) ( A ) and structural connectivity (median fractional anisotropy (FA)) ( B ) of intra- and interhemispheric connections within the frontostriatal system before (red) and after (blue) 7 days of daily saline/memantine treatment (control + saline: n = 8; control + memantine: n = 6; compulsive + saline: n = 7; compulsive + memantine: n = 7). Structural connectivity between the left and right frontal cortex could not be determined because of unreliable tractography results. Error bars represent 1.5 times the interquartile range and dots represent values that exceed 1.5 times the interquartile range

Article Snippet: Rats received daily intraperitoneal injections of the NMDA receptor antagonist memantine (20 mg/kg/day (Sekar et al. ), Boehringer Ingelheim Pharma, Germany) (compulsive + memantine group: n = 8, control + memantine group: n = 8) or saline (compulsive + saline group: n = 8, control + saline group: n = 8) for seven consecutive days, starting the day after the 10th quinpirole or saline injection.

Techniques: Functional Assay, Saline, Control, Transformation Assay

Journal: Psychopharmacology

Article Title: Memantine treatment does not affect compulsive behavior or frontostriatal connectivity in an adolescent rat model for quinpirole-induced compulsive checking behavior

doi: 10.1007/s00213-022-06139-z

Figure Lengend Snippet: Measures of compulsive checking behavior and body weight, before, and after saline/memantine treatment in control and compulsive rats. Compulsive behavior measures (frequency of checking (number of visits at the home base per minute (observed during 15 min for compulsive rats, and during 30 min for controls)), length of checks (average time (s) spent at the home base), recurrence time of checking (average time (s) before returning to the home base), stops before returning to the home base (average number of zones visited in between two visits of the home base)), entropy (predictability of the visited zones), and body weight (g), before (red), and after (blue) 7 days of daily saline/memantine treatment (control + saline: n = 8; control + memantine: n = 6; compulsive + saline: n = 7; compulsive + memantine: n = 7). Error bars represent 1.5 times the interquartile range, and dots represent values that exceeded 1.5 times the interquartile range

Article Snippet: Rats received daily intraperitoneal injections of the NMDA receptor antagonist memantine (20 mg/kg/day (Sekar et al. ), Boehringer Ingelheim Pharma, Germany) (compulsive + memantine group: n = 8, control + memantine group: n = 8) or saline (compulsive + saline group: n = 8, control + saline group: n = 8) for seven consecutive days, starting the day after the 10th quinpirole or saline injection.

Techniques: Saline, Control

Journal: Psychopharmacology

Article Title: Memantine treatment does not affect compulsive behavior or frontostriatal connectivity in an adolescent rat model for quinpirole-induced compulsive checking behavior

doi: 10.1007/s00213-022-06139-z

Figure Lengend Snippet: Brain activation directly after memantine/saline injection in control and compulsive rats. Brain activation maps, overlaid on anatomical images, show positive BOLD activation responses in yellow/red (z > 3.1) and negative responses in blue (z < − 3.1) ( A ). The normalized BOLD signal intensity (SI) time course is shown as averaged time series for the regions-of-interest, with the arrow indicating the time of memantine/saline injection ( B ). BOLD responses to memantine or saline injection quantified as area under the curve (AUC) (relative positive BOLD SI change per second) ( C ). Control + saline: n = 4; control + memantine: n = 12; compulsive + saline: n = 4; compulsive + memantine: n = 12. *Corrected p < 0.05. Shades in B represent the standard error. Error bars in C represent the standard deviation

Article Snippet: Rats received daily intraperitoneal injections of the NMDA receptor antagonist memantine (20 mg/kg/day (Sekar et al. ), Boehringer Ingelheim Pharma, Germany) (compulsive + memantine group: n = 8, control + memantine group: n = 8) or saline (compulsive + saline group: n = 8, control + saline group: n = 8) for seven consecutive days, starting the day after the 10th quinpirole or saline injection.

Techniques: Activation Assay, Saline, Injection, Control, Standard Deviation

Journal: Psychopharmacology

Article Title: Memantine treatment does not affect compulsive behavior or frontostriatal connectivity in an adolescent rat model for quinpirole-induced compulsive checking behavior

doi: 10.1007/s00213-022-06139-z

Figure Lengend Snippet: Brain activation directly after memantine injection following a single-quinpirole injection. Brain activation maps, overlaid on anatomical images, show positive BOLD activation responses in yellow/red (z > 3.1) and negative responses in blue (z < − 3.1) ( A ). The normalized BOLD signal intensity (SI) time-course is shown as averaged time series for the regions-of-interest, with the arrow indicating the time of memantine injection ( B ). BOLD responses to memantine injection quantified as area under the curve (AUC) (relative positive BOLD SI change per second) ( C ). Acute quinpirole + memantine: n = 8. Shades in B represent the standard error. Error bars in C represent the standard deviation

Article Snippet: Rats received daily intraperitoneal injections of the NMDA receptor antagonist memantine (20 mg/kg/day (Sekar et al. ), Boehringer Ingelheim Pharma, Germany) (compulsive + memantine group: n = 8, control + memantine group: n = 8) or saline (compulsive + saline group: n = 8, control + saline group: n = 8) for seven consecutive days, starting the day after the 10th quinpirole or saline injection.

Techniques: Activation Assay, Injection, Standard Deviation

Journal: Antioxidants

Article Title: N -Acetylaspartylglutamate (NAAG) Pretreatment Reduces Hypoxic-Ischemic Brain Damage and Oxidative Stress in Neonatal Rats

doi: 10.3390/antiox9090877

Figure Lengend Snippet: Effect of the application of group II mGluR antagonist LY341495 and NMDA receptor antagonist memantine (applied alone and in combination) on NAAG effect on the weight deficit of the ipsilateral hemisphere after HI. All drugs were applied i.p. 24 or 1 h before HI insult. The weight deficit is expressed as the percentage of the weight of the contralateral (right) hemisphere. The results are presented as the means ± SEM, n = 4–9; * p < 0.001 compared to the HI group; # p > 0.01 compared to the HI + NAAG group; & p > 0.005 comparison between NAAG + memantine applied at two different times before HI.

Article Snippet: The selective mGluR3 agonist N -acetylaspartylglutamate (NAAG) (5 mg/kg of body weight), group II mGluR selective antagonist LY341495 (1mg/kg of body weight) and NMDA receptors antagonist memantine (5 mg/kg of body weight) were administered intraperitoneally at 24 or 1 h before HI (all chemicals Tocris Bioscience, Bristol, UK).

Techniques: Comparison

Journal: Cell Death Discovery

Article Title: Xenon-mediated neuroprotection in response to sustained, low-level excitotoxic stress

doi: 10.1038/cddiscovery.2016.18

Figure Lengend Snippet: Role of NMDA glutamate receptors in xenon-mediated neuroprotection. ( a ) Survival rate of cortical neurons exposed to PDC (30 μ M) for 4 days and treated concurrently or not with the NMDA receptor blocker memantine (MEM, 10 μ M) or the amino acid glycine (1 mM) under a gas atmosphere containing 75% N 2 . Some cultures treated with PDC were also placed under a gas atmosphere containing 75% Xe and treated with or without glycine. Error bars indicate mean±S.E.M. (n =9 ). ***P <0.001 relative to control cultures under N 2 atmosphere and ### P <0.001 relative to PDC-treated cultures under N 2 atmosphere. ( b ) Survival of cortical neurons exposed to NMDA (100 μ M) for 4 days under 75% N 2 and the impact of a treatment with memantine (10 μ M) or 75% Xe. Error bars indicate mean±S.E.M. ( n =9). ***P <0.001 relative to control cultures maintained under N 2 atmosphere and ### P <0.001 relative to PDC-treated cultures under N 2 atmosphere. ( c ) Survival of cortical neurons exposed to PDC (30μM) for 4 days in the presence or not of various concentrations of memantine (0.1; 1; 10 μ M) or ketamine (0.01; 0.1; 1 μ M) under gas atmospheres containing either 75% N 2 or 75% Xe. Error bars indicate mean±S.E.M. ( n =9). ***P <0.001 relative to control cultures under N 2 atmosphere, ### P <0.001 relative to PDC-treated cultures under N 2 atmosphere; §§ P <0.01, §§§ P <0.001 relative to PDC-treated cultures maintained under 75% Xe and PDC-treated cultures maintained under 75% N 2 with a same concentration of memantine. ( d ) Fluorescence digitized images showing the impact that treatments with xenon alone or xenon+memantine (0.1; 10 μ M) exert on the survival of cortical cultures exposed to PDC. Scale bar 50 μ m.

Article Snippet: The non-metabolizable analog of L-glutamate PDC, the preferential agonist of NMDA receptors NMDA and the NMDA receptor antagonist memantine, were all purchased from Tocris Biotechne (Lille, France).

Techniques: Control, Concentration Assay, Fluorescence

Journal: Cell Death Discovery

Article Title: Xenon-mediated neuroprotection in response to sustained, low-level excitotoxic stress

doi: 10.1038/cddiscovery.2016.18

Figure Lengend Snippet: Impact of xenon on the uptake and release of [ 3 H]-D-aspartate in cortical cultures exposed to PDC. ( a ) [ 3 H]-D-aspartate uptake measured in cortical cultures exposed acutely or not to PDC (30 μ M) under an atmosphere containing 75% N 2 or 75% Xe, in the presence or not of memantine (10 μ M). Error bars indicate mean±S.E.M. ( n =6). ***P <0.001 relative to control cultures under N 2 atmosphere. ( b ) [ 3 H]-D-aspartate released in cortical cultures exposed or not to PDC (30 μ M) in an atmosphere containing 75% N 2 or 75% Xe, in the presence or not of memantine (10 μ M). Error bars indicate mean±S.E.M. ( n =9). ***P <0.001 relative to control cultures under N 2 atmosphere. Impact of an atmosphere containing 75% Xe on [ 3 H]-D-aspartate release evoked by a depolarizing treatment with 4-aminopyridine (4-AP; 2.5 mM) and bicuculline (Bic; 50 μ M). Error bars indicate mean±S.E.M. ( n =9). **P <0.01, ***P <0.001 relative to control cultures maintained under N 2 atmosphere.

Article Snippet: The non-metabolizable analog of L-glutamate PDC, the preferential agonist of NMDA receptors NMDA and the NMDA receptor antagonist memantine, were all purchased from Tocris Biotechne (Lille, France).

Techniques: Control

Journal: Cell Death Discovery

Article Title: Xenon-mediated neuroprotection in response to sustained, low-level excitotoxic stress

doi: 10.1038/cddiscovery.2016.18

Figure Lengend Snippet: Xenon prevents a death mechanism that implicates oxidative stress. ( a ) Survival of cortical neurons in cultures exposed or not to PDC (30 μ M) for 4 days and treated or not concomitantly with Trolox (10 μ M) or NAC (30 μ M) under an atmosphere containing 75% N 2 . Comparison with cultures receiving the same concentration of PDC under an atmosphere containing 75% Xe. Error bars indicate mean±S.E.M. ( n =6). ***P <0.001 relative to control cultures maintained under 75% N 2 and # P <0.05, ### P <0.001 relative to PDC-treated cultures maintained under 75% N 2 . ( b ) DPPH radical scavenging assay comparing the antioxidant potential of Trolox (10 μ M), NAC (30 μ M) and memantine (10 μ M) under 75% N 2 to that of an atmosphere containing 75% xenon. Error bars indicate mean±S.E.M. ( n =12). ***P <0.001 relative to controls maintained under 75% N 2 .

Article Snippet: The non-metabolizable analog of L-glutamate PDC, the preferential agonist of NMDA receptors NMDA and the NMDA receptor antagonist memantine, were all purchased from Tocris Biotechne (Lille, France).

Techniques: Comparison, Concentration Assay, Control, DPPH Radical Scavenging Assay

Journal: Cell Death Discovery

Article Title: Xenon-mediated neuroprotection in response to sustained, low-level excitotoxic stress

doi: 10.1038/cddiscovery.2016.18

Figure Lengend Snippet: Xenon exerts both neurotrophic and neuroprotective effects for cholinergic neurons in septal cultures. ( a ) Left panel: Size of ChAT + cell bodies in septal cultures exposed or not for 4 days to memantine (MEM; 10 μ M) under a gas atmosphere containing 75% N 2 or 75% Xe. Right panel: ChAT fluorescence intensity in ChAT + cell bodies exposed or not for 4 days to memantine (MEM; 10 μ M) under a gas atmosphere containing 75% N 2 or 75% Xe. Error bars indicate mean±S.E.M. ( n =25 randomly chosen neurons per condition). *** P <0.001 relative to control cultures maintained under 75% N 2 and § P <0.05 relative to cultures maintained under 75% Xe and to cultures maintained under 75% N 2 in the presence of memantine. ( b ) Fluorescence digitized images presented under an inverted format to illustrate the impact of the same treatments as in ( a ) onto cholinergic neurons. ( c ) Number of ChAT + neurons in septal cultures maintained for 4 days under a gas atmosphere containing 75% N 2 or 75% Xe and treated or not with PDC (30 μ M) in the presence or the absence of memantine (10 μ M). Error bars indicate mean±S.E.M. ( n =18). * P <0.05, *** P <0.001 relative to control cultures maintained under 75% N 2 ; ### P <0.001 relative to PDC-treated cultures maintained under 75% N 2 and §§ P <0.01 relative to PDC-treated cultures maintained in 75% Xe and PDC-treated cultures maintained in 75% N 2 in the presence of memantine. ( d ) Fluorescence digitized images showing the impact of the same treatments as in ( c ) onto cholinergic neurons. Scale bars: 25 μ m and 50 μ m in ( b ) and ( d ), respectively.

Article Snippet: The non-metabolizable analog of L-glutamate PDC, the preferential agonist of NMDA receptors NMDA and the NMDA receptor antagonist memantine, were all purchased from Tocris Biotechne (Lille, France).

Techniques: Fluorescence, Control